BioLife Solutions (NASDAQ:BLFS) Stock Rating Upgraded by StockNews.com

BioLife Solutions (NASDAQ:BLFS) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

Several other research analysts also recently commented on the company. HC Wainwright increased their price objective on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. KeyCorp increased their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Benchmark reissued a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, Northland Securities increased their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $29.86.

BioLife Solutions Stock Up 0.6 %

Shares of BLFS stock traded up $0.15 during trading hours on Wednesday, reaching $25.48. 264,571 shares of the company’s stock were exchanged, compared to its average volume of 349,394. BioLife Solutions has a 1 year low of $14.84 and a 1 year high of $29.55. The stock has a market cap of $1.20 billion, a PE ratio of -24.04 and a beta of 2.04. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock’s fifty day moving average price is $26.48 and its two-hundred day moving average price is $25.49.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. During the same quarter in the prior year, the firm earned ($0.21) earnings per share. Research analysts predict that BioLife Solutions will post -0.3 EPS for the current year.

Insiders Place Their Bets

In other news, CMO Todd Berard sold 1,577 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $39,425.00. Following the sale, the chief marketing officer now owns 104,961 shares of the company’s stock, valued at approximately $2,624,025. This trade represents a 1.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Troy Wichterman sold 987 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the sale, the chief financial officer now directly owns 121,779 shares in the company, valued at $3,290,468.58. This trade represents a 0.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,117 shares of company stock valued at $534,442 in the last three months. 2.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. D.A. Davidson & CO. grew its stake in shares of BioLife Solutions by 1.3% in the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock valued at $1,069,000 after purchasing an additional 519 shares during the last quarter. Stifel Financial Corp raised its holdings in shares of BioLife Solutions by 5.4% in the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after acquiring an additional 670 shares during the last quarter. 1620 Investment Advisors Inc. increased its stake in BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 675 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in BioLife Solutions by 27.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock valued at $117,000 after purchasing an additional 950 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC purchased a new stake in BioLife Solutions during the fourth quarter valued at about $26,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.